Literature DB >> 20636878

Usefulness of serum cystatin C to determine the dose of vancomycin in critically ill patients.

Akio Suzuki1, Yoshinori Imanishi, Shiho Nakano, Takashi Niwa, Tomofumi Ohmori, Kunihiro Shirai, Shozo Yoshida, Nobuyuki Furuta, Masao Takemura, Hiroyasu Ito, Ichiro Ieiri, Mitsuru Seishima, Shinji Ogura, Yoshinori Itoh.   

Abstract

OBJECTIVES: Serum creatinine (Scr) is not a reliable marker of renal function in critically ill patients because of an enhancement of protein catabolism, which makes it difficult to adjust the dosage of renally eliminated drugs such as antibiotics. This study aimed to investigate whether serum cystatin C (Scys-C) could be used as a reliable marker of renal function.
METHODS: We investigated whether Scys-C was a reliable marker of renal function in 56 critically ill patients. Subsequently, the usefulness of Scys-C to determine the initial loading and the maintenance dose of vancomycin was examined in 18 patients. Crea- tinine clearance (Ccr) was assessed from Scr and creatinine in urine collected over 24 h (24-h Ccr). KEY
FINDINGS: There was a good correlation between 24-h Ccr and 1/Scys-C (r(2) = 0.616), whereas less marked correlation was observed between 24-h Ccr and 1/Scr (r(2) = 0.221). On the other hand, vancomycin concentration was predicted from population pharmacokinetic parameters based on a two-compartment linear model. There were significant correlations between real trough concentrations of vancomycin and the values predicted from Scys-C using various equations (r(2) = 0.416-0.488), while less pronounced relationships were observed between real concentrations and the values predicted from Scr (r(2) = 0.134-0.187).
CONCLUSIONS: These findings suggest that Scys-C is a reliable marker reflecting renal function in critically ill patients and is applicable to determine the initial loading dose as well as the maintenance dose of vancomycin.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20636878     DOI: 10.1211/jpp.62.07.0011

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  6 in total

1.  Is Cystatin C Good Enough as a Biomarker for Vancomycin Dosing: A Pharmacokinetic Perspective.

Authors:  Guo Yu; Guo-Fu Li
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2020-02       Impact factor: 2.441

Review 2.  Cystatin C as a potential biomarker for dosing of renally excreted drugs.

Authors:  Nguessan Aimé Brou; Evelyne Jacqz-Aigrain; Wei Zhao
Journal:  Br J Clin Pharmacol       Date:  2015-05-28       Impact factor: 4.335

3.  Comparison of the Predictive Performance Between Cystatin C and Serum Creatinine by Vancomycin via a Population Pharmacokinetic Models: A Prospective Study in a Chinese Population.

Authors:  Ren Zhang; Ming Chen; Tao-Tao Liu; Jie-Jiu Lu; Chun-le Lv
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2020-02       Impact factor: 2.441

4.  Effect of Cystatin C on Vancomycin Clearance Estimation in Critically Ill Children Using a Population Pharmacokinetic Modeling Approach.

Authors:  Kevin J Downes; Nicole R Zane; Athena F Zuppa
Journal:  Ther Drug Monit       Date:  2020-12       Impact factor: 3.118

Review 5.  Biomarkers Predicting Tissue Pharmacokinetics of Antimicrobials in Sepsis: A Review.

Authors:  Maria Sanz Codina; Markus Zeitlinger
Journal:  Clin Pharmacokinet       Date:  2022-02-25       Impact factor: 5.577

6.  Serum cystatin C is a major predictor of vancomycin clearance in a population pharmacokinetic analysis of patients with normal serum creatinine concentrations.

Authors:  Jae-Yong Chung; Sung-Joon Jin; Ji-Hyun Yoon; Young-Goo Song
Journal:  J Korean Med Sci       Date:  2013-01-08       Impact factor: 2.153

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.